Literature DB >> 19710996

Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances.

V Pérez1, C Marin, A Rubio, E Aguilar, M Barbanoj, J Kulisevsky.   

Abstract

Parkinson's disease is a motor and cognitive disorder characterised by a progressive loss of the substantia nigra pars compacta (SNc) dopaminergic neurons as well as of the locus coeruleus (LC) noradrenergic neurons. It has been suggested that LC neurodegeneration might influence levodopa-induced motor disturbances and cognitive performance. We investigated the influence of dopaminergic and noradrenergic lesions on levodopa-induced dyskinesias and on working memory in rats. Two groups of animals were used: (1) rats with a dopaminergic lesion induced by a unilateral administration of the neurotoxin 6-hydroxydopamine (6-OHDA), and (2) rats with a combined lesion of the dopaminergic and noradrenergic systems induced by 6-OHDA and N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4), respectively. Dyskinesias were evaluated on days 1, 8, 15 and 22 of chronic levodopa treatment (6 mg/kg, twice at day, i.p.). Working memory was evaluated by a radial-arm maze (1) before lesions, (2) before levodopa administration and (3) after 22 days of levodopa treatment. Total, axial, limb and orofacial dyskinesias not differed significantly between both groups. Working memory tasks worsened in both lesioned groups reaching significance in terms of time of performance (P < 0.05). The number of repeated entries in the same arm (errors) was only significant in the double-lesioned group (P < 0.05). This behaviour was not different from the one observed after chronic levodopa treatment. These results suggest that levodopa-induced dyskinesias in the 6-OHDA-lesioned rats were not affected by the additional noradrenergic lesion, whereas this last condition was sufficient to worse the cognitive performance deficit produced by the dopaminergic lesion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19710996     DOI: 10.1007/s00702-009-0291-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  81 in total

Review 1.  Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions.

Authors:  Amy F T Arnsten; Bao-Ming Li
Journal:  Biol Psychiatry       Date:  2005-06-01       Impact factor: 13.382

2.  Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.

Authors:  C Pifl; G Schingnitz; O Hornykiewicz
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

Review 3.  Role of dopamine in the motivational and cognitive control of behavior.

Authors:  Roshan Cools
Journal:  Neuroscientist       Date:  2008-08       Impact factor: 7.519

4.  Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels.

Authors:  J Kulisevsky; A Avila; M Barbanoj; R Antonijoan; M L Berthier; A Gironell
Journal:  Brain       Date:  1996-12       Impact factor: 13.501

5.  The alpha2 agonist, clonidine, improves spatial working performance in Parkinson's disease.

Authors:  M Riekkinen; P Jäkälä; K Kejonen; P Riekkinen
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

6.  Fluctuations in plasma dopamine level impair memory in Parkinson's disease.

Authors:  S J Huber; H G Shulman; G W Paulson; E C Shuttleworth
Journal:  Neurology       Date:  1987-08       Impact factor: 9.910

7.  Levodopa and executive performance in Parkinson's disease: a randomized study.

Authors:  Berta Pascual-Sedano; Jaime Kulisevsky; Manel Barbanoj; Carmen García-Sánchez; Antonia Campolongo; Alexandre Gironell; Javier Pagonabarraga; Ignasi Gich
Journal:  J Int Neuropsychol Soc       Date:  2008-09       Impact factor: 2.892

8.  Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Authors:  Juha-Matti Savola; Michael Hill; Mia Engstrom; Hannele Merivuori; Siegfried Wurster; Steven G McGuire; Susan H Fox; Alan R Crossman; Jonathan M Brotchie
Journal:  Mov Disord       Date:  2003-08       Impact factor: 10.338

9.  Pharmacological basis of akinesia in Parkinson's disease.

Authors:  H Narabayashi
Journal:  J Neural Transm Suppl       Date:  1983

10.  Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals.

Authors:  J M Fritschy; R Grzanna
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

View more
  10 in total

1.  Human adipose-derived mesenchymal stem cells improve motor functions and are neuroprotective in the 6-hydroxydopamine-rat model for Parkinson's disease when cultured in monolayer cultures but suppress hippocampal neurogenesis and hippocampal memory function when cultured in spheroids.

Authors:  Jürgen Berg; Manfred Roch; Jennifer Altschüler; Christine Winter; Anne Schwerk; Andreas Kurtz; Barbara Steiner
Journal:  Stem Cell Rev Rep       Date:  2015-02       Impact factor: 5.739

2.  Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.

Authors:  Corinne Y Ostock; David Lindenbach; Adam A Goldenberg; Elias Kampton; Christopher Bishop
Journal:  Behav Brain Res       Date:  2014-05-13       Impact factor: 3.332

Review 3.  Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease.

Authors:  David Weinshenker
Journal:  Trends Neurosci       Date:  2018-02-20       Impact factor: 13.837

4.  The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study.

Authors:  Cristina Miguelez; Asier Aristieta; Maria Angela Cenci; Luisa Ugedo
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

5.  Noradrenaline and Parkinson's disease.

Authors:  Claire Delaville; Philippe De Deurwaerdère; Abdelhamid Benazzouz
Journal:  Front Syst Neurosci       Date:  2011-05-18

Review 6.  Noradrenergic dysfunction in Alzheimer's disease.

Authors:  Mary Gannon; Pulin Che; Yunjia Chen; Kai Jiao; Erik D Roberson; Qin Wang
Journal:  Front Neurosci       Date:  2015-06-17       Impact factor: 4.677

Review 7.  Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications.

Authors:  M Angela Cenci
Journal:  Front Neurol       Date:  2014-12-15       Impact factor: 4.003

Review 8.  The Noradrenergic System in Parkinson's Disease.

Authors:  Elena Paredes-Rodriguez; Sergio Vegas-Suarez; Teresa Morera-Herreras; Philippe De Deurwaerdere; Cristina Miguelez
Journal:  Front Pharmacol       Date:  2020-04-08       Impact factor: 5.810

Review 9.  Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease.

Authors:  Jelena Osmanovic Barilar; Ana Knezovic; Ana Babic Perhoc; Jan Homolak; Peter Riederer; Melita Salkovic-Petrisic
Journal:  J Neural Transm (Vienna)       Date:  2020-02-06       Impact factor: 3.575

10.  Desipramine protects neuronal cell death and induces heme oxygenase-1 expression in Mes23.5 dopaminergic neurons.

Authors:  Hsiao-Yun Lin; Wei-Lan Yeh; Bor-Ren Huang; Chingju Lin; Chih-Ho Lai; Ho Lin; Dah-Yuu Lu
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.